This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Diabetic Neuropathy Overview
- Therapeutics Development
- Pipeline Products for Diabetic Neuropathy - Overview
- Pipeline Products for Diabetic Neuropathy - Comparative Analysis
- Diabetic Neuropathy - Therapeutics under Development by Companies
- Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
- Diabetic Neuropathy Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Diabetic Neuropathy - Products under Development by Companies
- Diabetic Neuropathy - Products under Investigation by Universities/Institutes
- Diabetic Neuropathy - Companies Involved in Therapeutics Development
- Achelios Therapeutics, Inc.
- Araim Pharmaceuticals, Inc.
- Celgene Corporation
- Commence Bio, Inc.
- Glenmark Pharmaceuticals Ltd.
- Glucox Biotech AB
- Kineta, Inc.
- Lpath, Inc.
- Neuralstem, Inc.
- NovaLead Pharma Pvt. Ltd.
- Omeros Corporation
- PhiloGene, Inc.
- Reata Pharmaceuticals, Inc.
- Relief Therapeutics S.A.
- Sucampo Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- ViroMed Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/nrcvgk/diabetic